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Abstract
Background: Our recent study showed that tetrathiomolybdate (TM), a drug to treat copper overload disorders,
can sensitize drug-resistant endometrial cancer cells to reactive oxygen species (ROS)-generating anticancer drug
doxorubicin. To expand these findings in the present study we explore TM efficacy in combination with a
spectrum of ROS-generating anticancer drugs including mitomycin C, fenretinide, 5-fluorouracil and doxorubicin in
ovarian cancer cells as a model system.
Methods: The effects of TM alone or in combination with doxorubicin, mitomycin C, fenretinide, or 5-fluorouracil
were evaluated using a sulforhodamine B assay. Flow cytometry was used to detect the induction of apoptosis and
ROS generation. Immunoblot analysis was carried out to investigate changes in signaling pathways.
Results: TM potentiated doxorubicin-induced cytotoxicity and modulated key regulators of apoptosis (PARP,
caspases, JNK and p38 MAPK) in SKOV-3 and A2780 ovarian cancer cell lines. These effects were linked to the
increased production of ROS, as shown in SKOV-3 cells. ROS scavenging by ascorbic acid blocked the sensitization
of cells by TM. TM also sensitized SKOV-3 to mitomycin C, fenretinide, and 5-fluorouracil. The increased cytotoxicity
of these drugs in combination with TM was correlated with the activity of ROS, loss of a pro-survival factor (e.g.
XIAP) and the appearance of a pro-apoptotic marker (e.g. PARP cleavage).
Conclusions: Our data show that TM increases the efficacy of various anticancer drugs in ovarian cancer cells in a
ROS-dependent manner.
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Background
Ovarian cancer is the second most common gynecologi-
cal malignancy and the leading cause of gynecologic can-
cer deaths in the United States [1]. The initial treatment
for women diagnosed with ovarian cancer includes cytor-
eductive surgery followed by platinum based adjuvant
chemotherapy [2-4]. Although most women will have an
initial response to primary treatment, most will even-
tually experience a recurrence with the development of
chemoresistant disease. Improved chemotherapeutic
agents and sensitizers for resistant tumors are needed.
In the present report we assess the effect of ammonium
tetrathiomolybdate (TM) on the efficacy of a panel of
common anticancer drugs in combination treatment
against ovarian cancer cell lines in vitro. Due to the tetra-
hedral [MoS4]
2- anion, TM can function as a chelator
and was first therapeutically used to treat copper toxico-
sis in Wilson’s disease [5]. TM is known to decrease
angiogenesis and cancer cell growth through the inhibi-
tion of cellular antioxidant copper zinc superoxide dis-
mutase (SOD1) [6] and to elevate levels of cellular
reactive oxygen species (ROS) [7,8]. Recent studies
revealed that TM can also enhance the uptake and effi-
cacy of cisplatin in human ovarian tumors [9]. Details to
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TM in tumor animal studies activated pro-apoptotic
MAPK signaling, down regulated survival proteins, such
as XIAP, and reduced cancer cell motility and invasive-
ness [10]. TM, in phase I trials in patients with a variety
of metastatic cancers including breast, colon, lung, and
prostate and in phase II trials in patients with advanced
renal cancer and mesothelioma, was well tolerated and
showed stabilization of the disease in a proportion of
patients [11-13].
We recently reported that TM can sensitize drug-resis-
tant endometrial cancer cell lines to doxorubicin [7]. The
present study explores the ability of TM to potentiate the
effect of doxorubicin and several other anticancer drugs
including mitomycin C (MMC), fenretinide (4-HPR) and
5-fluorouracil (5-FU) in ovarian cancer cells. While these
four drugs differ with respect to their application to treat
ovarian cancer doxorubicin is used in recurrent disease,
MMC showed activity in phase II trials, and 5-FU and 4-
HPR showed positive responses in combination with plati-
num based drugs or as a single agent in phase II trials
respectively [14-17]. These drugs were chosen for this
study since they share one common target, the cellular
oxidative defense system. Treatment with any of these
drugs can lead to the elevation of oxidative stress promot-
ing cell death in cancer cells [7,18-21]. Their efficacy may
be improved if the oxidative balance in cancer cells is dis-
rupted by agents that target cellular antioxidants such as
TM. In the present study we describe the effect of TM
combination treatment with doxorubicin, 4-HPR, 5-FU,
and MMC on various cellular apoptotic markers and
determine the correlation between ROS activity and cell
death in ovarian cancer cells.
Methods
Cell lines, cell culture, and material
SKOV-3 (human ovarian adenocarcinoma) cells were pur-
chased from ATCC (Manassas, VA) and A2780 (human
ovarian adenocarcinoma) cells were supplied by Dr. Alex-
ander Brodsky (Brown University, Providence, RI). Both
cell lines were grown in Dulbecco’s modified eagle’s med-
ium (DMEM) supplemented with 10% fetal calf serum or
bovine calf serum and 1% penicillin/streptomycin; referred
to as a complete medium. Cells were cultured at 37°C
with 5% CO2 in a humidified incubator. Reagents were
purchased as follows: Sulforhodamine B (SRB), doxorubi-
cin, ammonium tetrathiomolybdate, phenylmethylsulfonyl
fluoride, ascorbic acid, propidium iodide, rhodamine 123,
4-HPR and 5-FU (Sigma Aldrich, Madison, WI); MMC
(Tocris Bioscience, Ellisville, MO); carboxy-H2DCFDA
(Invitrogen, Carlsbad, CA); trichloroacetic acid and acetic
acid (Fisher Scientific, Pittsburgh, PA); XIAP, JNK, p-JNK,
p38, p-p38, cleaved PARP, cleaved caspase-3 and -7 anti-
bodies were purchased from Cell Signaling Technologies
(Danvers, MA, USA). GAPDH antibody was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
SRB cell viability assay
Cells were plated into a 96-well microtiter plate in com-
plete medium and treated with TM (0, 30 μM) for 24 h,
after which the cells were treated with either doxorubi-
cin, MMC, 4-HPR, 5-FU of different concentrations and
durations as indicated. For treatment with doxorubicin
or MMC, 1 × 10
4 cells were seeded per well, for 4-HPR
and 5-FU 7.5 × 10
3 cells were seeded per well. Cell viabi-
lity, as represented by the amount of cell protein-bound
SRB, was measured as previously described [22].
Analysis of mitochondrial membrane potential (ΔΨm)
SKOV-3 cells (1 × 10
5) were seeded into 6-well plates
and treated with TM (0, 30 μM) after which the cells
were treated with doxorubicin (0, 5 μM) for another 24
h. The cells were incubated with rhodamine 123 (13 μM)
for 30 min at 37°C prior to completion of the drug treat-
ment. Rhodamine 123 is a cationic dye which localizes in
the mitochondria of viable cells. The cells were harvested,
resuspended in medium containing propidium iodide
(7.5 μM) and analyzed by flow cytometry. Data was
acquired on a BD FACSort flow cytometer using Cell-
Quest software (BD Immunocytometry-Systems, San
Jose, CA) and analyzed (ModFit LT software, Verity Soft-
ware House, Inc., Topsham, ME). Ten thousand cells
were analyzed for each sample.
Western blot Analysis
SKOV-3 or A2780 cells were treated with TM and
anticancer drugs (doxorubicin, MMC, 4-HPR or 5-FU)
alone and in combination under the conditions indi-
cated. Cells were lysed, protein concentration of the
lysates quantified, proteins separated by NuPAGE sys-
tem (Invitrogen, Carlsbad, CA), and immunoblotted as
described previously [7].
Detection of intracellular ROS
SKOV-3 cells (3 × 10
5/well) were seeded into 6-well
plates and treated with TM (0, 30 μM) for 24 h, after
which the cells were additionally treated with doxorubi-
cin (0, 10 μM) for another 5.5 h and the assay carried out
as described previously [23]. After treatment, the cells
were incubated with carboxy-H2DCFDA (25 μM) for 30
min at 37°C with 5% CO2. Carboxy-H2DCFDA is the
acetylated form of a reduced fluorescein derivative that is
cell-permeable and becomes fluorescent in the presence
of cellular oxidants. Cells were harvested and resus-
pended in phosphate buffered saline buffer before being
analyzed by flow cytometry.
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Tetrathiomolybdate increases the sensitivity of ovarian
cancer cell lines to doxorubicin
To evaluate whether TM can sensitize ovarian cancer cells
toward doxorubicin treatment, the SRB assay was carried
out. Platinum resistant SKOV-3 ovarian cancer cells were
treated with TM (0, 30 μM) for 24 h, after which the cells
were treated with doxorubicin (0, 2.5, 5, 10 μM) for
another 24 h. Cells treated solely with doxorubicin (follow-
ing vehicle pre-treatment for 24 h) at all concentrations
tested reduced cell proliferation by 29% as compared to
untreated controls (Figure 1a). Cells treated solely with
TM (30 μM) reduced cell viability by 5%. Pre-treatment
with TM followed by treatment with doxorubicin revealed
significant sensitization with viability inhibited by 42.1%
(2.5 μM doxorubicin), 62.0% (5 μM) and 79.1% (10 μM).
To verify TM-mediated sensitization of ovarian cancer
cells to doxorubicin, platinum sensitive A2780 cells were
treated as described above with the exception that TM
was applied at the concentration of 7.5 μM. (Figure 1b).
Treatment with TM alone resulted in 14% reduction of
viability while doxorubicin alone exerted effects in a dose-
dependent manner (41.7% viability reduction at 2.5 μM;
50% at 5 μM; 58.7% at 10 μM doxorubicin). The TM/dox-
orubicin combination revealed significant sensitization of
A2780 cells with viability inhibited by 74.8% (2.5 μM dox-
orubicin), 87.5% (5 μM) or 97.1% (10 μM). Taken together,
our results suggest that TM treatment sensitizes ovarian
cancer cells to doxorubicin treatment in vitro.
Doxorubicin-mediated apoptosis in ovarian cancer cells is
enhanced by pre-treatment with TM
We carried out flow cytometry of drug treated cells (TM,
doxorubicin, TM/doxorubicin combination) to measure a
potential loss of mitochondrial membrane potential
(ΔΨm), an irreversible event during the process of apopto-
sis [24,25]. SKOV-3 cells were double-stained to detect
cells with active mitochondria ΔΨm, and to detect non-
viable cells. As shown in Figure 1c, the cells treated with
TM alone (30 μM, 48 h) only displayed minimal change in
ΔΨm and remained mostly viable (Q4; 94.7%). Similarly,
the majority of cells treated with doxorubicin alone
remained mostly viable (Q4; 78.0%) with 8.1% of cells (Q1
+ Q2) being dead and an additional 13.9% displaying a dis-
rupted ΔΨm (Q3). In contrast, treatment with TM (30 μM,
24 h), followed by additional treatment with doxorubicin
(5 μM, 24 h) increased the population of dead cells to
15.2% (Q1 + Q2) and also increased the population of
cells with a disrupted ΔΨm to 26.8% (Q3).
To define the cellular response of SKOV-3 cells upon
TM and doxorubicin treatment we analyzed the activa-
tion of caspases characteristic for induction of apopto-
s i sa sw e l la st h ei n a c t i v a t i o no fP A R P ,aD N Ar e p a i r
factor, by immunoblotting. SKOV-3 cells were treated
with TM (0, 30 μM) for 24 h, after which the cells
were treated with doxorubicin (0, 5 μM) for 1, 4, 7 or
24 h as indicated (Figure 1d, left panel). PARP inactiva-
tion/cleavage and caspase-7 activation were observed
when SKOV-3 cells were treated with doxorubicin
alone for 24 h. TM/doxorubicin combination treat-
ment, however, led to a strong detection of cleaved
caspase-3 and to an increased level of activated cas-
pase-7 and inactivated PARP when compared to doxor-
ubicin treatment alone (Figure 2d, left panel). The
same procedure was employed to treat A2780 cells
(Figure 2d, right panel) with different concentrations of
TM (7.5 μM) and doxorubicin (2.5 μM). Similarly to
SKOV-3 cells, the most prominent cleavage of these
apoptotic markers was found when A2780 cells were
treated with TM/doxorubicin combination. Collec-
tively, these results verify that TM sensitizes ovarian
cancer cells to doxorubicin therapy and potentiates cell
death via induction of apoptosis.
An increased generation of intracellular ROS upon TM/
doxorubicin combination treatment causes ovarian cancer
cell death
One potential strategy suggested to treat cancer is to gen-
erate an excess amount of ROS in tumor tissue to induce
cell death. We determined if SKOV-3 cell treatment with
either TM or doxorubicin alone or in combination led to
excess generation of ROS via flow cytometry. As shown
in Figure 2a, ROS generation was slightly elevated over
baseline after treatment with TM alone (shift in relative
fluorescence intensity). Doxorubicin alone also caused a
peak shift, which was further increased when the cells
were first treated with TM followed by doxorubicin
treatment.
To confirm that the generation of ROS by TM/doxoru-
bicin combination treatment is the predominant mechan-
ism of cytotoxic action we performed viability assays with
SKOV-3 cells in the absence or presence of antioxidant
ascorbic acid. As shown in Figure 2b the growth inhibitory
effect of TM was not notably affected by ascorbic acid
treatment (90.2% viability with ascorbic acid; 88.1% with-
out). Similarly, scavenging of ROS did not reduce the cyto-
toxic action (70.4% viability with ascorbic acid; 68.9%
without) by doxorubicin treatment. In contrast, in TM/
doxorubicin combination treatment, ascorbic acid partially
restored the viability (69.9% viability with ascorbic acid;
42.6% without) (Figure 2b).
The potentiation of JNK and p38 activation by TM/
doxorubicin combination treatment is ROS-dependant
JNK and p38 are key regulators of stress-mediated apop-
tosis and activation of these MAPK takes a center stage
in cellular response to treatment with TM/doxorubicin
as shown recently for endometrial cancer cells in vitro
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native and activated/phosphorylated JNK or p38 MAPK
we analyzed the effect of TM/doxorubicin treatment on
ovarian cancer cells. SKOV-3 cells were treated with
TM (0, 30 μM) for 24 h, after which the cells were trea-
ted with doxorubicin (0, 5 μM) for various time periods
as indicated (Figure 3a, left panel). The same procedure
was employed to treat A2780 cells with different
concentrations of TM (0, 7.5 μM) and doxorubicin (0,
2.5 μM) (Figure 3a, right panel). TM alone did not
cause a change of JNK or p38 activation in SKOV-3 or
A2780 cells. When cells were treated with doxorubicin
for 24 h in combination with TM, a drastic increase in
the activation of both MAPKs, compared to their activa-
tions in the cells treated by either TM or doxorubicin
alone, was observed (Figure 3a).
Figure 1 Combinational treatment of ovarian cancer cell lines with TM and doxorubicin reduces cell viability via promotion of
apoptotic signaling. SKOV-3 (a) or A2780 (b) ovarian cancer cells were treated with TM (0, 30 μM for SKOV-3; 0, 7.5 μM for A2780) for 24 h,
after which the cells were treated with doxorubicin (0, 2.5, 5, 10 μM) for another 24 h. Cell viability was evaluated as described in Methods. Data
are expressed as the mean of the triplicate determinations (X ± SD) compared to untreated cells [100%]. (c) SKOV-3 cells were treated with TM
(0, 30 μM) for 24 h, after which the cells were treated with doxorubicin (0, 5 μM) for another 24 h. The change in the mitochondrial membrane
potential (ΔΨm) was measured by flow cytometry. Intact cells = Q4, Loss of ΔΨm = Q3, ruptured cell membrane = Q1 and Q2. (d) SKOV-3 cells
(left panel) were treated with TM (0, 30 μM) for 24 h, after which the cells were treated with doxorubicin (0, 5 μM) for 1, 4, 7 or 24 h as
indicated. The same procedure was employed to treat A2780 cells (right panel) with different concentrations of TM (0, 7.5 μM) and doxorubicin
(0, 2.5 μM). Immunoblotting was carried out with primary antibodies against cleaved PARP, caspase-3, and -7. As an internal standard for equal
loading blots were probed with an anti-GAPDH antibody.
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caused by the drugs alone or in combination potentiated
the MAPK activations described above, we employed
antioxidant ascorbic acid (750 μM) alongside to TM (30
μM) and doxorubicin (5 μM) treatment. As shown in
Figure 3b, the potentiation of JNK and p38 activation
upon TM/doxorubicin combination treatment was
clearly attenuated by ascorbic acid, resulting in decreased
kinase activation levels similar to those found in the cells
treated with doxorubicin alone. Furthermore, the strong
inactivation of PARP (an indicator for apoptotic pro-
cesses) observed upon TM/doxorubicin combination
treatment was blocked by ascorbic acid co-treatment
and, thus, ROS dependent (Figure 3b). In summary,
increased ROS generation caused by TM/doxorubicin
combination potentiated cytotoxic effects (viability assay;
Figure 2b) and pro-apoptotic signaling.
TM induces sensitivity of ovarian cancer cells to various
anticancer drugs via promotion of apoptotic signaling
and ROS generation
A multitude of commonly used anticancer drugs display
mechanistic features similar to those ascribed to doxor-
ubicin when used to treat cells in vitro, such as the
Figure 2 Generation of intracellular ROS in ovarian cancer cells after individual or combinational treatment with TM and doxorubicin.
(a) SKOV-3 cells were treated with TM (0, 30 μM) for 24 h, after which the cells were treated with doxorubicin (0, 10 μM) for another 5.5 h.
Generation of intracellular ROS was measured by flow cytometry (see Methods). Data are presented as relative fluorescence intensity (DCF). (b)
SKOV-3 cells were treated with TM (0, 30 μM) for 24 h, after which the cells were treated with doxorubicin (0, 5 μM) for another 24 h in the
presence or absence of radical scavenger ascorbic acid (750 μM) before the viability of cells was measured. Data are expressed as the mean of
the triplicate determinations (X ± SD) compared to untreated cells [100%].
Figure 3 Activation of pro-apoptotic JNK and p38 MAPK after TM/doxorubicin treatment with or without inhibition of ROS. (a) SKOV-3
cells (left panel) were treated with TM (0, 30 μM) for 24 h, after which the cells were treated with doxorubicin (0, 5 μM) for 1, 4, 7 or 24 h as
indicated. The same procedure was employed to treat A2780 cells (right panel) with different concentrations of TM (0, 7.5 μM) and doxorubicin
(0, 2.5 μM). Immunoblotting was carried out with primary antibodies against native and activated/phosphorylated JNK or p38 MAPK. As an
internal standard for equal loading blots were probed with an anti-GAPDH antibody. (b) SKOV-3 cells were treated as described in (a) in the
presence or absence of radical scavenger ascorbic acid (750 μM). Immunoblotting was carried out with primary antibodies against JNK, p-JNK,
p38, p-p38, cleaved PARP or GAPDH.
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if TM potentially can sensitize cancer cells to a panel of
d r u g si n c l u d i n gM M C ,4 - H P R ,a n d5 - F U .S K O V - 3c e l l s
were treated with TM (0, 30 μM) for 24 h, after which
the cells treated for another 24 h with MMC or another
48 h with 4-HPR or 5-FU (Figure 4a). Cells treated
solely with MMC (2.5, 5, 10 μM), similarly to doxorubi-
cin, did not show a clear dose response (Figure 1a) and
reduced cell viability by only 27% as compared to
untreated controls. 4-HPR exerted dose-dependent cyto-
toxicity on SKOV-3 cells (viability of 83.1% at 5 μM;
50.4% at 10 μM). 5-FU displayed partial effects (viability
of 78.3% at 1 mM). As seen for doxorubicin, treatment
with TM potentiated the cytotoxic effect of all three
drugs tested. Under these conditions the viability was
reduced to 48.2% (TM + 10 μM MMC), 40.3% (TM +
5 μM 4-HPR) and 48.2% (TM + 1 mM 5-FU), respec-
tively (Figure 4a). In summary, depending on the drug
and concentration used, TM increased the cytotoxicity
between 1.6 and 2.9 fold after collecting the effect of
TM alone (Table 1). Our experiments suggest that TM
treatment improves the response of ovarian cancer cells
to doxorubicin, MMC, 4-HPR, and 5-FU treatment
in vitro.
To confirm that the potentiation of the cytotoxicity of
these drugs by TM treatment is accompanied by
Figure 4 TM increases ROS mediated cytotoxicity of various anticancer drugs in ovarian cancer cells. (a) SKOV-3 cells were treated with
TM (0, 30 μM) for 24 h, after which the cells were treated for another 24 h with MMC or for another 48 h with 4-HPR or 5-FU in the
concentrations indicated. The cell viability was evaluated as described in Methods. Data are expressed as the mean of the triplicate
determinations (X ± SD) compared to untreated cells [100%]. (b) SKOV-3 cells were treated with TM (0, 30 μM) for 24 h, after which the cells
were treated for another 24 h with doxorubicin (0, 5 μM), MMC (0, 5 μM), 4-HPR (0, 10 μM) or 5-FU (0, 1000 μM). Immunoblotting was carried
out with primary antibodies against cleaved PARP, pro-survival marker XIAP or GAPDH as internal control for equal loading. (c) SKOV-3 cells were
treated with TM (0, 30 μM) for 24 h, after which the cells were treated for another 24 h with MMC (0, 5 μM) or for another 48 h with 4-HPR (0, 5
μM) or 5-FU (0, 1000 μM) in the presence or absence of radical scavenger ascorbic acid (750 μM).
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vation/cleavage of PARP, a DNA repair factor, and
expression of the X-linked inhibitor of apoptosis (XIAP),
by immunoblotting. SKOV-3 cells were treated with TM
(0, 30 μM) for 24 h, after which the cells were treated
with doxorubicin (0, 5 μM), MMC (0, 5 μM), 4-HPR (0,
10 μM) or 5-FU (0, 1000 μM) for another 24 h. As
shown, PARP inactivation/cleavage over background
levels (untreated controls) was observed for individual
treatment with MMC, 4-HPR, and 5-FU (Figure 4b) as
shown for doxorubicin (Figure 1d) but not for TM
treatment. Combination treatment of SKOV-3 cells with
TM potentiated the effects of all drugs tested on PARP.
PARP was partially inactivated/cleaved after TM/5-FU
treatment and drastically inactivated after TM/MMC,
TM/4-HPR (Figure 4b) and TM/doxorubicin (Figure 1d)
treatment. XIAP expression was reduced after TM/5-FU
and barely detectable after TM/doxorubicin, TM/MMC
and TM/4-HPR combination treatment (Figure 4b). In
summary, TM sensitized ovarian cancer cells to treat-
ment with these four anticancer drugs and potentiated
cell death via induction of apoptosis.
We showed that the generation of ROS by TM/doxoru-
bicin combination treatment is a key mechanism of cyto-
toxic action (Figure 2) in ovarian cancer cells. To assess if
ascorbic acid can similarly quench the effects of 5-FU,
MMC and 4-HPR when combined with TM, we per-
formed viability assays using SKOV-3 cells. Cells were
treated with TM (0, 30 μM) for 24 h, after which the cells
were treated with MMC (0, 5 μM) for another 24 h or 4-
HPR (0, 5 μM) or 5-FU (0, 1000 μM) for another 48 h. As
shown in Figure 4c scavenging of ROS by ascorbic acid
did not significantly reduce the partial cytotoxic effects of
any single drug. In contrast, upon TM/MMC combination
treatment, ascorbic acid restored cell viability effectively
from 51.0 to 78.1%. Upon TM/4-HPR treatment, ascorbic
acid restored cell viability dramatically from 37.6 to 94.1%.
Upon TM/5-FU treatment, ascorbic acid restored the via-
bility effectively from 22.7 to 51.3% (Figure 4c).
Discussion
The present report reveals that combination treatment of
ovarian cancer cells in vitro with TM improved the effi-
cacy of a panel of anticancer drugs, namely doxorubicin,
MMC, 4-HPR and 5-FU. We recently reported that TM
sensitized drug-resistant endometrial cancer cell lines to
doxorubicin [7] similar to ovarian cancer cells. Doxorubi-
cin is among the most widely used agents to treat
tumors, including lymphomas, leukemias, lung, breast,
and ovarian cancers [16]. Doxorubicin is classified as a
topoisomerase II inhibitor but its cytotoxic mechanisms
remain unclear. The interaction of doxorubicin with cel-
lular iron and its quinone moiety with oxo-reductive
enzymes leads to the formation of radicals and excessive
generation of ROS promoting cancer cell death
[7,21,26,27]. It has been proposed that the pharmacologi-
cal suppression of cellular antioxidants or elevation of
ROS levels can sensitize tumor cells to doxorubicin
[28,29] as shown here by combination treatment with
TM. Such a treatment modality would provide a benefit
to cancer patients because the use of doxorubicin and
other anticancer agents is often challenged by concentra-
tion-dependent toxic effects [30]. Interestingly, indepen-
dent of improved anti-tumor efficacy, TM treatment was
shown in mice to protect against doxorubicin-induced
cardiac toxicity [31]. Cardiotoxicity is the major limiting
factor in the clinical use of doxorubicin implicating that
combination therapy with TM may also provide clinical
benefits secondary to the mitigation of doxorubicin toxi-
city during chemotherapy. Similar to doxorubicin, MMC
contains a quinone moiety and leads to radical formation
in vitro [19]. In addition, as for doxorubicin, the efficacy
of MMC in ovarian cancer cells was improved and was
linked to an increased ROS activity when the cells were
treated in combination with TM as shown in the present
report. MMC was originally isolated as an antibiotic from
Streptomyces and is a potent DNA cross-linker classify-
ing it as a potential agent to treat a broad range of solid
tumors [32]. Phase II trials of low-dose MMC in patients
with refractory ovarian cancer revealed higher survival
rates and no significant toxicity [14]. MMC has also suc-
cessfully been used alongside other drugs such as irinote-
can (topoisomerase inhibitor) to treat refractory ovarian
cancer [33]. Because TM was well tolerated in patients
with Wilson disease and in phase I and II trials to treat
patients with a variety of different tumors [11-13,34], and
based on our findings we suggest to establish trials to
treat resistant and/or refractory ovarian cancer by combi-
nation therapy with TM and doxorubicin or alternatively
with MMC.
TM in ovarian cancer cells also potentiated the effect of
the pyrimidine analog 5-FU which acts as a thymidylate
synthase inhibitor, thereby strongly affecting rapidly
dividing cancerous cells [35]. It has been shown pre-
viously that 5-FU can improve the efficacy of platinum
based drugs in combination for the treatment of ovarian
cancer [15,36]. 5-FU in these studies was well tolerated
and can be used at relatively high concentrations without
toxic side effects. The effects of anticancer drugs that are
Table 1 Effect of drug combinations on SKOV-3 cell
viability
Cell Viability
[% of Untreated Control]
DOX
[10 μM]
MMC
[10 μM]
4-HPR
[5 μM]
5-FU
[1 mM]
No TM 70.7% 73.0% 83.1% 78.3%
With TM, 30 μM 20.9% 48.2% 40.3% 48.2%
Cytotoxicity Increase 2.5 fold 1.6 fold 2.9 fold 1.9 fold
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related to the induction of pro-apoptotic signaling and
the generation of oxidative stress [7,20]. In the present
report, the mild cytotoxicity displayed by 5-FU as a single
agent was ROS independent while TM/5-FU combina-
tion treatment led to a significant ROS based reduction
of ovarian cancer cell viability suggesting that expanded
in vitro studies are needed to establish the parameters for
the use of these two drugs in animal tumor models.
Similarly, our study suggests that the combination
treatment with 4-HPR and TM can be considered to
treat ovarian or other cancers. 4-HPR is a synthetic reti-
noid with antitumor activity and is known to cause cellu-
lar metabolic perturbations and induction of apoptosis in
ovarian and other cancer cells via ROS-dependent
mechanisms involving ER stress and MAPK (e.g. JNK)
activation [18,37]. In recent phase II trials, patients with
recurrent ovarian and primary peritoneal carcinoma
received 4-HPR. It was well tolerated and displayed clini-
cal responses [17]. Based on our findings, ovarian tumors
may be sensitized to the treatment with 4-HPR by combi-
nation treatment with TM. Because both drugs were well
tolerated by patients in previous studies, we suggest
exploring the efficacy of TM/4-HPR in animal tumor
models and ultimately in clinical applications.
As shown in the present report, TM increases the effi-
cacy of doxorubicin, MMC, 4-HPR and 5-FU in ovarian
cancer cells. Accordingly, lower concentrations of these
drugs are needed to cause significant cytotoxicity. A simi-
lar effect during in vivo treatments could potentially
reduce administered doses and toxic side effects of these
or other anticancer drugs when combined with TM. The
drug effects of doxorubicin, MMC, 4-HPR or 5-FU are
potentiated when TM is co-applied to the cells unless an
antioxidant is added; proving that increased ROS genera-
tion is responsible for drug action when used in combina-
tion. ROS are byproducts of normal cellular metabolism
and tightly regulated in balance with cellular antioxidants.
Cancer cells, through mitochondria dysfunction and
increased metabolism, generate a relatively high level of
ROS [38,39]. Further elevation of cellular ROS beyond a
toxic threshold, as shown here after combinational treat-
ment with TM, is an attractive strategy to selectively target
tumor cells during chemotherapy [40,41]. These phenom-
ena are not unique to TM combination treatment because
ROS generation is a key mechanism of apoptosis for a
variety of common chemotherapeutic drugs such as dau-
norubicin, cyclophosphamide or cisplatin [42-44]. Poten-
tially, combination treatment of TM with doxorubicin,
MMC, 4-HPR, or 5-FU may exert additional synergistic
effects when combined with other agents thought to mod-
ulate the antioxidant functions of cancer cells such as
2-methoxyestradiol (SOD inhibitor) or drugs leading to
glutathione depletion such as buthionine-sulfoximine.
This approach might, in particular, be applied to treat
MDR tumors because, for example, SOD1 is a therapeutic
target of TM [6] and inhibition of SOD1 was shown to
restore the cisplatin-sensitivity in resistant ovarian cancer
cells [45]. It has been reported that chemotherapy-induced
generation of ROS is often correlated with activation of
the JNK and p38 MAPK signaling pathways [46,47] which
play a crucial role in the response of ovarian cancer cells
to common anticancer agents such as cisplatin [48]. Even
though a detailed analysis of the modulation of these sig-
naling pathways is beyond the scope of the present report
we conducted a limited study to the effect of one drug
combination (TM/doxorubicin) on the activation of these
apoptotic markers in ovarian cancer cells. Combination
treatment led to a dramatic increase of JNK and p38 acti-
vation which could be blocked by ROS scavenging and,
thus, was directly correlated to the increase of ROS levels.
Accordingly, apart from the destabilization of the cellular
oxidative defense system, the subsequent potentiation of
stress kinase signals also plays a vital role in the improved
efficacy by TM combination therapy.
Conclusions
The present study reveals that TM increases the efficacy
of various anticancer drugs in multi-drug resistant ovar-
ian cancer cells in a ROS-dependent manner. In addi-
tion, to the study of medical applications of TM, as
discussed in the previous sections, we suggest to expand
the analysis of biochemical and mechanistic effects of
TM combination therapy in vitro and in animal tumor
models. These may include the use of redox-modulating
agents, cell lines derived from refractory ovarian or
other cancers, and a broader panel of cancer drugs. Ulti-
mately, the use of TM or TM-derivatives in combina-
tion therapy may improve current cancer treatment
options.
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